Key Insights

Highlights

Success Rate

83% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

3.1%

1 terminated out of 32 trials

Success Rate

83.3%

-3.2% vs benchmark

Late-Stage Pipeline

13%

4 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed with results

Key Signals

1 with results83% success

Data Visualizations

Phase Distribution

20Total
Not Applicable (16)
P 3 (1)
P 4 (3)

Trial Status

Unknown12
Recruiting11
Completed5
Active Not Recruiting2
Enrolling By Invitation1
Terminated1

Trial Success Rate

83.3%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (32)

Showing 20 of 20 trials
NCT07287176Not ApplicableRecruiting

Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System

NCT07484087Not ApplicableRecruiting

Ablation Compare With Surgery for Early Breast Cancer

NCT07094256Not ApplicableRecruiting

Torque Device Evaluation

NCT07361081Active Not Recruiting

Protocol-Driven Continuous Infusion Versus Intermittent Bolus Heparin During Atrial Fibrillation Ablation

NCT04893278Enrolling By Invitation

Virtual Reality in Electrophysiology Laboratory (EP)

NCT06959121Not ApplicableRecruiting

CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation

NCT07238894Not ApplicableRecruitingPrimary

A Cohort Study of Combined Cryoablation and Thermal Ablation for Non-surgical Treatment of Breast Cancer Patients

NCT07240441Not ApplicableRecruiting

Endo-ePIcardial Versus Endocardial Only Catheter Ablation for ISchemic Driven Ventricular Tachycardia (EPISODE VT)

NCT06172699Active Not Recruiting

Assert-IQ Implantable Cardiac Monitor (ICM) Post Market Study

NCT06609850Not ApplicableRecruiting

The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma

NCT06644430Recruiting

Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma

NCT06516822Not ApplicableRecruiting

CPVI With Modified Linear Ablation Versus CPVI in Patients With Long-standing Persistent Atrial Fibrillation (SINUS)

NCT06550921Not ApplicableRecruiting

Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

NCT06231160Unknown

Clinical Comparative Study of Systematic Therapy Combined With MWA and Systematic Therapy for Pancreatic Cancer

NCT06134739Unknown

Arterial Embolism After Catheter Ablation of Atrial Fibrillation. ATRIAL FIBRILLATION

NCT05498779Completed

Ablation of Hepatocellular Carcinoma: a Nationwide Study

NCT05848635Phase 4Unknown

Hydromorphone for Perioperative Analgesia in Lung Tumor Ablation Parallel Controlled

NCT04293198Completed

Evaluating the Performance of the KODEX-EPD CRyOballoon Occlusion Feature in Patients With Atrial Fibrillation

NCT05698576Not ApplicableRecruiting

TRANBERG® Transperineal MR/US Fusion Laser--Induced Thermal Therapy for Men With Prostate Cancer

NCT05073744Phase 4Unknown

Nalbuphine Versus Morphine for Perioperative Tumor Ablation

Scroll to load more

Research Network

Activity Timeline